Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Carcinogenicity of anticancer agents].

Y Hayashi1, M Takahashi, H Yoshimura

  • 1Division of Pathology, National Institute of Hygienic Sciences.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 1, 1990
PubMed
Summary

Chemotherapy with alkylating agents improves cancer survival but increases the risk of secondary cancers, such as acute non-lymphatic leukemia. This paper addresses challenges in developing and using anticancer drugs to prevent these secondary malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary blastoma. Comparison between its epithelial components and fetal bronchial epithelium.

Acta pathologica japonica·1992
Same author

A new metabolite of 2,4,3',4'-tetrachlorobiphenyl in rat feces.

Chemical & pharmaceutical bulletin·1992
Same author

Sex difference in hepatic microsomal aldehyde oxygenase activity in different strains of mice.

Research communications in chemical pathology and pharmacology·1992
Same author

Tissue-specific expression, induction, and inhibition through metabolic intermediate-complex formation of guinea pig cytochrome P450 belonging to the CYP2B subfamily.

Archives of biochemistry and biophysics·1992
Same author

[Metabolite of 15-p-iodophenyl-3(R,S)-pentadecanoic acid (123I) in blood and urine].

Kaku igaku. The Japanese journal of nuclear medicine·1992
Same author

Metabolism of 2,4,5,2',4',5'-hexachlorobiphenyl with liver microsomes of phenobarbital-treated dog; the possible formation of PCB 2,3-arene oxide intermediate.

Xenobiotica; the fate of foreign compounds in biological systems·1992

Area of Science:

  • Oncology
  • Cancer Therapeutics
  • Carcinogenesis

Context:

  • Chemotherapy, particularly with alkylating agents, is a cornerstone of cancer treatment, significantly improving patient survival rates.
  • However, long-term survivors treated with these agents face an elevated risk of developing secondary malignancies.
  • Acute non-lymphatic leukemia is a predominant second cancer observed in these patients.

Purpose:

  • To highlight practical challenges encountered during the development of novel anticancer agents.
  • To discuss clinical use considerations for existing and new chemotherapeutic drugs.
  • To focus on strategies for preventing the occurrence of second cancers in cancer survivors.

Summary:

  • This paper examines the dual nature of alkylating agent chemotherapy: its efficacy in prolonging survival versus its potential to induce secondary cancers.

Related Experiment Videos

  • It identifies key issues in the research and clinical application of anticancer drugs concerning secondary cancer prevention.
  • Practical problems in drug development and clinical deployment are discussed in the context of mitigating this risk.

    • Impact:

    • Informing oncologists and researchers about the risks associated with specific chemotherapy regimens.
    • Guiding the development of safer anticancer agents with reduced secondary cancer induction potential.
    • Improving long-term patient outcomes by addressing the prevention and management of treatment-related secondary malignancies.